Acrobiosystems Co

Acrobiosystems Co EV/Revenue

The EV/Revenue (Enterprise Value to Revenue) of Acrobiosystems Co (301080.SZ) as of Nov 11, 2026 is 11.81. In the previous year, EV/Revenue (Enterprise Value to Revenue) was 15.26 — a change of -22.61% (lower).

EV/Revenue

11.81

YoY

-22.61%

Last updated:

EV/Revenue (Enterprise Value to Revenue) of Acrobiosystems Co is 2025 11.81 . EV/Revenue (Enterprise Value to Revenue) of Acrobiosystems Co was 2024 15.26 . It decreases by -22.61% lower compared to the previous year.

The Acrobiosystems Co EV/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/Revenue
Date
EV/Revenue
Jan 1, 2018
140.48 CNY
Jan 1, 2019
95.31 CNY
Jan 1, 2020
39.97 CNY
Jan 1, 2021
25.57 CNY
Jan 1, 2022
20.75 CNY
Jan 1, 2023
18.11 CNY
Jan 1, 2024
15.26 CNY
Jan 1, 2025
11.81 CNY
The Acrobiosystems Co EV/Revenue history
YEAREV/RevenueYoY
11.81-22.61%
15.26-15.72%
18.11-12.73%
20.75-18.85%
25.57-36.02%
39.97-58.07%
95.31-32.15%
140.48—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

EV/Revenue (Enterprise Value to Revenue) of Acrobiosystems Co is 11.81 in 2025.

EV/Revenue (Enterprise Value to Revenue) of Acrobiosystems Co changed from 15.26 to 11.81, representing a -22.61% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/Revenue (Enterprise Value to Revenue) Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

The EV/Revenue ratio compares a company's enterprise value to its total revenue. It is particularly useful for valuing high-growth companies that may not yet be profitable.

To evaluate EV/Revenue (Enterprise Value to Revenue)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/Revenue (Enterprise Value to Revenue).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/Revenue (Enterprise Value to Revenue)'s Acrobiosystems Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co